Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates

Signal Transduct Target Ther. 2024 Nov 20;9(1):327. doi: 10.1038/s41392-024-02058-x.

Leonie Mayer^{1

2

3}, Leonie M Weskamm^{4

5

6}, Marylyn M Addo^{7

8

9}

¹ Institute for Infection Research and Vaccine Development (IIRVD), Center for Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. l.mayer@uke.de.
² Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany. l.mayer@uke.de.
³ German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany. l.mayer@uke.de.
⁴ Institute for Infection Research and Vaccine Development (IIRVD), Center for Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. m.weskamm@uke.de.
⁵ Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany. m.weskamm@uke.de.
⁶ German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany. m.weskamm@uke.de.
⁷ Institute for Infection Research and Vaccine Development (IIRVD), Center for Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁸ Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
⁹ German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.

No abstract available

Grants and funding